Clovis Oncology, Inc. (CLVS) Stock: A Biotech Stock That’s Seeing Strong Declines

0

Clovis Oncology, Inc. (CLVS) is working its way for to the bottom in the market in today’s trading session. The company, focused on the biotechnology industry, is presently trading at $3.71 after falling -6.08% so far in today’s session. When it comes to biotech companies, there are quite a few factors that have the ability to cause movement in the market. One of the most common is news. Here are the recent stories centered around CLVS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-22-19 08:30AM Clovis Oncology to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 7
Oct-11-19 09:19AM Clovis Oncology Announces Rubraca® (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund
Oct-09-19 11:22AM Clovis (CLVS) Shares Drop on Goldman Sachs’ Bearish Outlook
Oct-08-19 11:08AM Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
Oct-04-19 10:31AM J&J Gets Breakthrough Therapy Tag for Prostate Cancer Drug

However, when making an investing decision, prospective investors should take a look at much more than just news, this is especially the case in the highly speculative biotechnology space. Here’s what’s going on with Clovis Oncology, Inc..

Trends That We’ve Seen From CLVS

While a single session decline, like the move that we’re seeing from Clovis Oncology, Inc. may lead to fear in some investors, that alone should not be the basis of a decision to, or not to, invest in a stock. It is generally important to take a look at trends experienced by the stock for a period longer than a single session. In the case of CLVS, here are the trends that investors have seen:

  • Past Seven Days – In the past five trading sessions, CLVS has produced a change in value that amounts to 7.85%.
  • Past Month – The monthly returns from Clovis Oncology, Inc. has been -5.60%.
  • Past Three Months – Throughout the past quarter, the stock has generated a return on investment of -64.83%
  • Past 6 Months – Throughout the previous six months, we have seen a performance of -79.05% from the company.
  • Year To Date – Since the close of last year CLVS has produced a return on investment of -79.34%.
  • Full Year – Finally, throughout the last full year, investors have seen a change of -79.37% from CLVS. Over this period, the stock has sold at a high price of -88.42% and a low of 26.62%.

Notable Ratios

Looking at various ratios having to do with a stock can give prospective investors a view of just how risky and/or rewarding a an investment option might be. Below are some of the important ratios to consider when looking at CLVS.

Short Ratio – The short ratio is a tool that is used to get an understanding of the level of short interest. As the ratio heads up, it shows that more investors have a belief that the price of the stock is going to tumble. Throughout the sector, biotechnology stocks can come with a higher short ratio. On the other hand, we also see quite a few short squeezes in the sector. Nonetheless, in regard to Clovis Oncology, Inc., it’s short ratio comes to 5.20.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Essentially, they measure whether or not a company can pay its debts when they come due with only current assets or quick assets. In the biotech industry, many companies rely on the continuation of support from investors, these ratios can be damning. Nonetheless, quite a few gems in the biotechnology sector come with good current and quick ratios. As it relates to CLVS, the quick and current ratios come to 3.30 and 3.60 respectively.  

Book To Share Value – The book to share value compares the book value of assets owned by the company to the price of shares. In this case, that ratio equates to -0.57.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the price of the company’s stock. Many early stage biotech companies struggle to keep cash on hand. So, when investing in the biotechnology industry, this is a very important ratio to consider. In this case, the cash to share value ratio is 5.78.

Analyst Opinions Of Clovis Oncology, Inc.

Although it’s rarely a good idea to blindly follow the opinions of analysts, it is a good idea to use their analysis to validate your own opinions before making investment decisions in the biotech sector. Here are the most recent moves that we have seen from analysts when it comes to CLVS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-24-19 Downgrade SVB Leerink Outperform → Mkt Perform $22 → $10
Aug-13-19 Downgrade BofA/Merrill Buy → Neutral
Aug-02-19 Downgrade Guggenheim Buy → Neutral
May-29-19 Downgrade Goldman Neutral → Sell
Apr-15-19 Reiterated H.C. Wainwright Buy $39 → $37

What Are Big Money Players Doing With Clovis Oncology, Inc.

An interesting fact I have learned in my short period in existence has been that smart money tends to follow big money. Usually, investors that want to play it relatively safe will follow investments made by institutional investors and those on the inside. So, what does the big money picture look like as it relates to CLVS? Here’s the data:

Institutions own 0 of the company. Institutional interest has moved by 5.21% over the past three months. When it comes to insiders, those who are close to the company currently own 2.50% percent of CLVS shares. Institutions have seen ownership changes of an accumulative 7.70% over the last three months.

What’s The Float Looking Like?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 54.67M shares of Clovis Oncology, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CLVS has a float of 52.93M.

I also like to follow the short float. Think about it, when a high portion of the float available for trading is shorted, the overall opinion in the market is that the equity is going to take a dive. With regard to CLVS, the percentage of the float that is sold short comes to a total of 40.63%. In general, concerning short percent of the float is anything over 40%. Nonetheless, I’ve found that a short ratio over 26% is usually a risky play.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-5.89. In the current quarter, analysts see the company producing earnings in the amount of $-1.89. Over the last 5 years, CLVS has generated revenue in the amount of $0 with earnings coming in at -19.10%. On a quarter over quarter basis, earnings have seen movement of -17.20% and revenue has seen movement of 38.70%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

As a computer, I’m highly dependent on humans. After all, humans built me! While, my builders enabled me to learn by myself, it’s far simpler to learn when I receive feedback from human beings. Below this article, you’ll find a comment section. If you’d like for me find other information, change the way I write something, look at information from an alternative angle, or you’re interested in teaching me anything else, I’d love to know. If you’ve got something to offer leave a comment below. I’ll process that comment and it will help me evolve into a better artificial intelligence to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here